Fulvestrant

被引：32

作者：

Curran M. ^{[1
]}

Wiseman L. ^{[1
]}

机构：

[1] Adis International Limited, Mairangi Bay, Auckland 10

来源：

Drugs | 2001年 / 61卷 / 6期

关键词：

Tamoxifen; Advanced Breast Cancer; Anastrozole; Fulvestrant; Endometrial Thickness;

D O I：

10.2165/00003495-200161060-00013

中图分类号：

学科分类号：

摘要：

Fulvestrant is a 7α-alkylsulphinyl analogue of estradiol that competes with endogenous estrogen for binding to the estrogen receptor. Once bound to the receptor, fulvestrant attenuates receptor dimerisation, effecting a rapid degradation of the estrogen receptor protein and inhibition of transcription. Fulvestrant is a potent inhibitor of the growth of human breast cancer cells in vitro and in vivo. It has demonstrated pure anti-estrogenic activity in animal systems. Intramuscular fulvestrant 250mg once a month was as effective as the oral aromatase inhibitor anastrozole 1 mg/day in 2 phase III trials in postmenopausal women with advanced breast cancer who had received prior endocrine therapy. Median time to disease progression (the primary end-point) with fulvestrant and anastrozole was 5.4 and 3.4 months (North American trial) and 5.5 and 5.1 months (European trial). The median duration of response was 19.3 and 10.5 months (North American trial) and 14.3 and 14.0 months (European trial). The most common adverse events with fulvestrant are gastrointestinal disturbances and hot flushes. Fulvestrant showed similar tolerability to anastrozole in 2 phase III trials.

引用

页码：807 / 813

页数：6

共 32 条

[1]

Wakeling A.E., Dukes M., Bowler J., A potent specific pure antiestrogen with clinical potential, Cancer Res, 51, 15, pp. 3867-3873, (1991)

[2]

Wakeling A.E., Bowler J., Steroidal pure antioestrogens, J Endocrinol, 112, (1987)

[3]

Parker M.G., Action of "pure" antiestrogens inhibiting estrogen receptor action, Breast Cancer Res Treat, 26, pp. 131-137, (1993)

[4]

Fawell S.E., White R., Hoare S., Et al., Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization, Proc Natl Sci USA, 87, pp. 6883-6887, (1990)

[5]

Gibson M.K., Nemmers L.A., Beckman W.C., Et al., The mechanism of ICI 164384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue, Endocrinology, 129, pp. 2000-2010, (1991)

[6]

Dauvois S., Danielian P.S., White R., Et al., Antiestrogenic ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover, Proc Natl Acad Sci USA, 89, pp. 4037-4041, (1992)

[7]

Dauvois S., White R., Parker M.G., The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling, J Cell Sci, 106, pp. 1377-1388, (1993)

[8]

De Cupis A., Noonan D., Pirani P., Et al., Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells, Br J Pharmacol, 116, pp. 2391-2400, (1995)

[9]

Lykkesfeldt A.E., Madsen M.W., Briand P., Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAM<sup>R-</sup>l<sup>1</sup>, Cancer Res, 54, pp. 1587-1595, (1994)

[10]

Coradini D., Biffi A., Cappelletti V., Et al., Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells, Anticancer Res, 14, pp. 1059-1064, (1994)

← 1 2 3 4 →